Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
Theranostics · 2023
DOI: 10.7150/thno.79367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2023. Verfasst von Rongjuan Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai 201210, China. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Bispecific. Die Arbeit wurde bisher 49-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai 201210, China.
- Beijing Kohnoor Science & Technology Co., Ltd., Beijing 102206, China.
- School of Life Sciences, Anhui University, Hefei 230022, China.
Zitieren
APA
Wang, R., Zhang, C., Cao, Y., Wang, J., Jiao, S., Zhang, J., Wang, M., Tang, P., Ouyang, Z., Liang, W., Mao, Y., Wang, A., Li, G., Zhang, J., Wang, M., Wang, S., & Gui, X. (2023). Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment. Theranostics. https://doi.org/10.7150/thno.79367
Vancouver
Wang R, Zhang C, Cao Y, Wang J, Jiao S, Zhang J, et al. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment. Theranostics. 2023. doi:10.7150/thno.79367
BibTeX
@article{Wang2023,
author = {Wang, Rongjuan and Zhang, Chang and Cao, Yuting and Wang, Junchao and Jiao, Shasha and Zhang, Jiao and Wang, Min and Tang, Peipei and Ouyang, Zijun and Liang, Wenlu and Mao, Yu and Wang, An and Li, Gang and Zhang, Jinchao and Wang, Mingzhu and Wang, Shuang and Gui, Xun},
title = {Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment},
journal = {Theranostics},
year = {2023},
doi = {10.7150/thno.79367}
}
EUVIMED